Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Last trade$2.00
Day change+$0.08 (+4.17%)
Day range$1.81 – $2.04
Volume189,125
Market cap$87M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$86.87M
Price / earnings
—
Price / book
9.47×
Price / sales
10,858.88×
EV / sales
9,678.26×
EV / EBITDA
-2.01×
Profitability
Earnings per share
-$0.84
Return on assets
-184.02%
Return on equity
-413.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.16×
Quick ratio
1.16×
Cash ratio
1×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GNLX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$8K
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$8K
$0
$0
$0
$0
Selling, general and administrative
$3.49M
$3.14M
$3.39M
$3.77M
$3.45M
$3.03M
$3.12M
$3.23M
Research and development
$6.91M
$6.51M
$5.78M
$5.65M
$4.74M
$4.76M
$4.7M
$6.52M
Total operating expenses
$10.4M
$9.65M
$9.17M
$9.42M
$8.19M
$7.79M
$7.82M
$9.75M
Operating income
-$10.4M
-$9.65M
-$9.17M
-$9.41M
-$8.19M
-$7.79M
-$7.82M
-$9.75M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$10.29M
-$9.47M
-$8.93M
-$9.25M
-$7.95M
-$7.46M
-$7.49M
-$8.98M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$10.29M
-$9.47M
-$8.93M
-$9.25M
-$7.95M
-$7.46M
-$7.49M
-$8.98M
Net income attributable to common shareholders
-$10.29M
-$9.47M
-$8.93M
-$9.25M
-$7.95M
-$7.46M
-$7.49M
-$8.98M
EBITDA
-$10.39M
-$9.63M
-$9.16M
-$9.35M
-$8.13M
-$7.73M
-$7.76M
-$9.69M
Basic earnings per share
-$0.23
-$0.21
-$0.20
-$0.24
-$0.21
-$0.20
-$0.21
-$0.26
Diluted earnings per share
-$0.23
-$0.21
-$0.20
-$0.24
-$0.21
-$0.20
-$0.21
-$0.26
Recent news
Company coverage with links to the original publishers.
Genelux Corporation announced that its President, CEO, and Chairman Thomas Zindrick, along with CFO Matt Pulisic and Chief Medical Officer Dr. Jason Litten, will participate in a virtual fireside chat on January 19, 2026. The company is a late clinical-stage biopharmaceutical firm developing oncolytic immunotherapies, with its lead candidate Olvi-Vec currently in Phase 2 and Phase 3 clinical trials for ovarian cancer, non-small-cell lung cancer, and small-cell lung cancer.
Genelux Corporation announced the appointment of Jason Litten, M.D., as Chief Medical Officer effective January 2, 2026. Dr. Litten brings over 20 years of biopharmaceutical experience and will oversee clinical development and medical strategy for Olvi-Vec, the company's oncolytic immunotherapy candidate currently in Phase 2/3 trials for ovarian and lung cancers.
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, Chairman and CEO will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones at the H.C. Wainwright Global Healthcare Conference.
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, CEO and Chairman will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024.
Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
0
Last 30D
0
1
0
0
0
1M Ago
1
0
0
0
0
2M Ago
1
1
0
0
0
3M Ago
0
0
0
0
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.75, a high estimate of $32.00, and a low estimate of $25.00. This current average represents a 8.46% decrease from the previous average price target of $32.50.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Genelux among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Bruce Jackson
Benchmark
Lowers
Speculative Buy
$25.00
$30.00
Emily Bodnar
HC Wainwright & Co.
Maintains
Buy
$32.00
-
Bruce Jackson
Benchmark
Maintains
Speculative Buy
$30.00
-
Emily Bodnar
HC Wainwright & Co.
Lowers
Buy
$32.00
$35.00
Key Insights:
Action Taken: In response to ...Full story available on Benzinga.com
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.